AstraZeneca antibody cocktail fails to prevent Covid-19 symptoms in late-stage trial

AstraZeneca’s antibody cocktail was only 33% effective at preventing Covid-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker's pandemic push.

AstraZeneca said on Tuesday a late-stage trial failed to provide evidence that its Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines. The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing Covid-19 symptoms. The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.